vTv Therapeutics Company Profile (NASDAQ:VTVT)

About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VTVT
  • CUSIP: N/A
  • Web: www.vtvtherapeutics.com
Capitalization:
  • Market Cap: $48.27 million
  • Outstanding Shares: 9,693,000
Average Prices:
  • 50 Day Moving Avg: $5.34
  • 200 Day Moving Avg: $5.52
  • 52 Week Range: $4.65 - $7.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $287,999.00
  • Price / Sales: 167.61
  • Book Value: ($12.74) per share
  • Price / Book: -0.39
Profitability:
  • EBIDTA: ($55,000,000.00)
  • Net Margins: -1,882.12%
  • Return on Assets: -21.15%
Debt:
  • Current Ratio: 4.93%
  • Quick Ratio: 4.93%
Misc:
  • Average Volume: 21,548 shs.
  • Beta: 0.99
  • Short Ratio: 11.81
 

Frequently Asked Questions for vTv Therapeutics (NASDAQ:VTVT)

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. The business earned $0.03 million during the quarter, compared to analysts' expectations of $0.20 million. View vTv Therapeutics' Earnings History.

Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?

4 brokerages have issued 1-year price targets for vTv Therapeutics' shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' share price to reach $16.50 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

What are analysts saying about vTv Therapeutics stock?

Here are some recent quotes from research analysts about vTv Therapeutics stock:

  • 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (5/9/2017)
  • 2. Canaccord Genuity analysts commented, "We update our model and reiterate our BUY. Pivotal Ph3 azeliragon Alzheimer’s data in 2018; Part B recruitment to complete in June 2017. Part A completed enrollment in mid-16. Ph3 STEADFAST is an 18-month, randomized, double-blind, placebo-controlled study assessing whether oral, once-daily RAGE antagonist azeliragon slows cognitive/functional decline in 400 mild Alzheimer’s Disease (AD) patients on standard-of-care (SOC; acetylcholinesterase inhibitor and/or memantine). Co-primary endpoints include change from baseline in AD Assessment Scale-cognitive subscale (ADAS-Cog11) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb). As a reminder, the Ph2b assessing SOC +/- 5mg azeliragon daily for 18 months showed patients receiving azeliragon had significantly lower ADAS-Cog11 and CDR-sb score decline, with greater benefit in mild patients, and significantly fewer psychiatric events." (2/28/2017)

Who are some of vTv Therapeutics' key competitors?

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who owns vTv Therapeutics stock?

vTv Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (4.56%), Sphera Funds Management LTD. (3.10%), Vanguard Group Inc. (2.99%), Ameriprise Financial Inc. (1.68%), Candriam Luxembourg S.C.A. (1.44%) and Sabby Management LLC (1.28%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

Who sold vTv Therapeutics stock? Who is selling vTv Therapeutics stock?

vTv Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC, Morgan Stanley, TIAA CREF Investment Management LLC and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for vTv Therapeutics.

Who bought vTv Therapeutics stock? Who is buying vTv Therapeutics stock?

vTv Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Sphera Funds Management LTD., Essex Investment Management Co. LLC, Renaissance Technologies LLC, Bank of New York Mellon Corp, Vanguard Group Inc., Geode Capital Management LLC and Ameriprise Financial Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

How do I buy vTv Therapeutics stock?

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of vTv Therapeutics stock cost?

One share of vTv Therapeutics stock can currently be purchased for approximately $4.98.

Analyst Ratings

Consensus Ratings for vTv Therapeutics (NASDAQ:VTVT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (231.33% upside)

Analysts' Ratings History for vTv Therapeutics (NASDAQ:VTVT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
3/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$24.00LowView Rating Details
2/28/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
12/15/2016Stifel NicolausSet Price TargetBuy$14.00N/AView Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for vTv Therapeutics (NASDAQ:VTVT)
Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Earnings History by Quarter for vTv Therapeutics (NASDAQ:VTVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.44)($0.44)$0.20 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)$0.38 millionViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-2.29 EPS

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.17%
Institutional Ownership Percentage: 12.18%
Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Paul G SavasDirectorBuy3,000$5.18$15,540.00View SEC Filing  
3/31/2017Paul G SavasDirectorBuy10,000$6.50$65,000.00View SEC Filing  
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for vTv Therapeutics (NASDAQ:VTVT)
Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to vTv Therapeutics, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 7:38 PM
americanbankingnews.com logoPaul G. Savas Acquires 3,000 Shares of vTv Therapeutics Inc (VTVT) Stock
www.americanbankingnews.com - May 15 at 10:34 PM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 7 at 7:42 AM
finance.yahoo.com logovTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 6 at 1:29 AM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - May 5 at 2:31 PM
finance.yahoo.com logoETFs with exposure to vTv Therapeutics, Inc. : May 4, 2017
finance.yahoo.com - May 5 at 3:30 AM
finance.yahoo.com logovTv Therapeutics Reports First Quarter 2017 Financial and Operational Results
finance.yahoo.com - May 3 at 6:54 PM
finance.yahoo.com logoVTv Therapeutics reports 1Q loss
finance.yahoo.com - May 3 at 6:54 PM
americanbankingnews.com logovTv Therapeutics (VTVT) Given Coverage Optimism Rating of -0.39
www.americanbankingnews.com - May 2 at 1:18 PM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 27 at 11:40 PM
americanbankingnews.com logovTv Therapeutics (VTVT) Receives Coverage Optimism Score of 0.31
www.americanbankingnews.com - April 27 at 11:54 AM
americanbankingnews.com logovTv Therapeutics (VTVT) Earns News Sentiment Rating of 0.31
www.americanbankingnews.com - April 20 at 3:06 PM
americanbankingnews.com logovTv Therapeutics (VTVT) Receives News Impact Score of -0.10
www.americanbankingnews.com - April 13 at 1:18 PM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Short Interest Update
www.americanbankingnews.com - April 7 at 8:00 PM
finance.yahoo.com logoETFs with exposure to vTv Therapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 1:25 PM
americanbankingnews.com logovTv Therapeutics' (VTVT) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 5 at 8:58 AM
americanbankingnews.com logoHC Wainwright Reaffirms Buy Rating for vTv Therapeutics Inc (VTVT)
www.americanbankingnews.com - April 4 at 9:14 AM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Director Purchases $65,000.00 in Stock
www.americanbankingnews.com - April 3 at 8:26 PM
americanbankingnews.com logovTv Therapeutics Inc (VTVT) Receives Overweight Rating from Piper Jaffray Companies
www.americanbankingnews.com - March 30 at 6:22 PM
americanbankingnews.com logoHC Wainwright Reiterates "Buy" Rating for vTv Therapeutics Inc (VTVT)
www.americanbankingnews.com - March 30 at 9:05 AM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 29 at 10:09 AM
finance.yahoo.com logovTv Therapeutics to Present at Two Upcoming Annual Investor Conferences
finance.yahoo.com - March 11 at 11:07 AM
us.rd.yahoo.com logovTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
us.rd.yahoo.com - February 28 at 11:07 AM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 25 at 4:20 AM
finance.yahoo.com logovTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
finance.yahoo.com - January 25 at 4:27 PM
us.rd.yahoo.com logovTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
us.rd.yahoo.com - December 15 at 7:13 AM
us.rd.yahoo.com logo4:33 pm vTv Therapeutics announces 'positve' data from its Phase 2 study evaluating TTP273 for the treatment of Type 2 diabetes; Oral small molecule GLP-1 receptor agonist met primary endpoint
us.rd.yahoo.com - December 15 at 7:13 AM
streetinsider.com logovTv Therapeutics (VTVT) to Present New Small Molecule Drug Candidate Data as PD Treatment at Upcoming Conference
www.streetinsider.com - November 16 at 12:14 PM
finance.yahoo.com logoNew Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
finance.yahoo.com - November 16 at 12:14 PM
finance.yahoo.com logo9:15 am vTv Therapeutics to present new pre-clinical data on a vTv Therapeutics small molecule drug candidate against Parkinson's Disease
finance.yahoo.com - November 16 at 12:14 PM
finance.yahoo.com logoCan JD.com (JD) Stock Surprise Investors in Q3 Earnings?
finance.yahoo.com - November 14 at 12:34 PM
finance.yahoo.com logoVTV THERAPEUTICS INC. Financials
finance.yahoo.com - November 10 at 8:20 PM
finance.yahoo.com logovTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences
finance.yahoo.com - November 10 at 8:20 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - November 2 at 8:48 PM
biz.yahoo.com logoVTV THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
biz.yahoo.com - October 31 at 8:48 AM
finance.yahoo.com logovTv Therapeutics to Present at Peptide Therapeutics Symposium
finance.yahoo.com - October 24 at 7:39 PM
finance.yahoo.com logovTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 8 at 11:57 AM

Social

Chart

vTv Therapeutics (VTVT) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff